Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, cilt.18, ss.233-234, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Özet
- Cilt numarası: 18
- Basım Tarihi: 2022
- Dergi Adı: ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
- Sayfa Sayıları: ss.233-234
- Hacettepe Üniversitesi Adresli: Evet